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Abstract. Background/Aim: Vascular endothelial growth
inhibitor (VEGI) is a multipotential cytokine that plays a role
in regulating immunity, anti-angiogenesis, and inhibiting
tumor growth. However, the proteins that interact with it are
still unknown. In the present study, we examined the proteins
which interact with VEGI174 and their expressions in renal
cell carcinoma (RCC). Materials and Methods: The proteins
that interact with VEGI174 were identified using western
blot, pull-down assay, and mass spectrometry. The
expressions of VEGI174 and the interacting proteins were
examined in RCC and were compared with normal renal
tissues using immunochemical staining and RNA-seq
respectively. Results: The results of the mass spectrometric
analysis showed that ACLY, ENO1, ZIK1, AKR1C3, and
MYC may interact with VEGI174. When compared with the
TCGA database, the expression level of VEGI174 in RCC
was lower than that in normal kidney using RNAseq
(p<0.001). The expression levels of ACLY, ENO1, ZIK1,
AKR1C3 and MYC in RCC were higher than that in normal
kidney (p<0.05, all of above factors). Moreover,
immunochemical staining results also showed that the
expression level of AKR1C3 in RCC was significantly higher
than that in normal kidney (p<0.001) and was also positively
correlated with higher RCC stage and grade. Conclusion:
Taken together, our findings showed that VEGI174 may
interact with ACLY, ENO1, ZIK1, AKR1C3, and MYC. The
expression of ACLY, ENO1, AKR1C3 and MYC is increased
in RCC. AKR1C3 was a new factor that may correlate with
the progression of RCC. The results indicated that VEGI174
has more functions than we currently know in the
development and progression of RCC.
Vascular endothelial growth inhibitor, VEGI (also known as
tumor necrosis factor superfamily member 15 (TNFSF15)
and TNF ligand related molecule 1 (TL1)), is an anti-
angiogenic cytokine that belongs to the TNFSF family of
proteins (1-3). Three isoforms of VEGI (VEGI 174,
VEGI192, VEGI 251) have been reported, all of them
sharing a common region of 453bp that encodes a domain of
151 amino acids at the C-terminus but they differ in their N-
terminal regions (4-6). The biological activity of VEGI
mainly depends on the solubilised extracellular domain of
the three isoforms. VEGI is a multipotential cytokine that
plays a role in inflammation, septic shock, fever, and growth
modulation through inducing apoptosis, regulating immunity
and anti-angiogenesis. Thus, VEGI may play a role as a
target for anti-tumor growth via its inhibitory role on anti-
angiogenesis and regulating immunity (7). Many evidences
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have also shown that overexpression of VEGI could inhibit
tumor neovascularisation and progression in cellular and
animal models (2, 8). 
First, VEGI is able to inhibit the growth of various human
tumor cell lines including human histiocytic lymphoma (U-
937), human breast carcinoma (MCF-7), human epithelial
carcinoma (HeLa) and human myeloid lymphoma ML-1a
(9).  Second, VEGI is shown to inhibit tumor growth in
vivo. It also suppresses the growth of colon carcinoma cells
(murine colon cancer cells, MC-38) both in vitro and in vivo
(2, 3, 10). Systemic administration of VEGI 192 remarkably
inhibited tumor growth and increased survival time of
treated animals in a Lewis lung carcinoma (LLC) murine
tumor model (11). In 2006, Parr et al. reported that patients
with breast tumors expressing reduced levels of VEGI had
a higher local recurrence, shorter survival time and an
overall poorer prognosis than patients expressing higher
levels of VEGI (7). In 2013, Jia et al. reported that the
expression level of VEGI was significantly lower in
pituitary tumors which invaded the sellafloor, and with
suprasellar extension than that of non-invasive tumors (12).
They suggested that VEGI was an independent indicator for
invasion in human pituitary adenomas. Our previous studies
demonstrated that VEGI expression could significantly
reduce motility and adhesion of renal, prostate and bladder
cancer cells (13, 14). VEGI expression was decreased in
renal cell carcinoma (RCC), particularly in high-grade
tumors. Furthermore, full length VEGI174 could suppress
the growth of RCC in vivo (15-17). In addition, VEGI is
also a T-cell co-stimulator and can directly stimulate
dendritic cell maturation (8, 18). However, it is still unclear
whether activation of tumor specific or non-specific B or T
lymphocytes may operate in soluble VEGI-mediated tumor
suppression.
It is well known that tumor angiogenesis and immunity
are closely related with RCC progression. Our studies
showed that VEGI174 might be a putative tumor suppressor
and a potential therapeutic target for RCC. However, it is
unclear whether VEGI174 acts solely or in collaboration
with other proteins as part of a protein complex. In this
study, the proteins that interact with VEGI174 were
identified by immunoprecipitation and mass spectrometry.
The expression of VEGI174 and associated proteins was also
examined in RCC tissues using the RNA-seq method.
Materials and Methods
Cell lines. All cell lines used in this study were purchased from the
American Type Culture Collection (ATCC, Rockville, MD, USA).
Human emborynic kidney 293 T cell line (HEK293T) and Chinese
hamster ovarian line (CHO) were used in this study. Cells were
routinely cultured with Dubecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum, penicillin and
streptomycin (Gibco BRC, Paisley, UK).
Antibodies. Antibodies were purchased from the following sources:
The monoclonal anti-Flag M2 Tag was purchased from Sigma-
Aldrich Co. LLC. (F1804, Sigma-Aldrich Co. LLC., St. Louis,
USA). The monoclonal Rabbit anti-human-ACLY (ATP citrate
lyase) and anti-human-ENO1 (Enolase 1) antibodies were purchased
from Abcam Inc. (EP704Y and EPR10863, Abcam Inc., Cambridge
Science Park, UK). The monoclonal mouse anti-human-VEGI174
antibody was purchased from LSBio Inc. (LS-C76815, LSBio Inc.,
Seattle, WA, USA). Monoclonal mouse anti-human-AKR1C3
(Aldo-ketoreductase family 1 member C3) antibody was kindly
supplied by Professor Qing from the Centre for Cellular &
Structural biology, School of Pharmaceutical Sciences, Sun Yat-Sen
University, Guangzhou, P.R. China.
Human RCC specimens. A total of 16 pairs of renal cell carcinoma
and normal renal tissue samples were snap-frozen in liquid nitrogen
immediately after radical nephrectomy. The pathologist verified
normal and cancer specimens. All protocols were reviewed and
approved by local ethics committee and all patients were given
written informed consent. Nine patients were in clinical stage T1
and 7 patients were in T3. In addition, 1 patient was in Fuhrman
Grade l, 8 patients were in Fuhrman Grade 2, 6 patients were in
Fuhrman Grade 3, and 1 patient was in Fuhrman Grade 4. 
RNA isolation and reverse transcription PCR. RNA was isolated
using Total RNA Isolation reagent (ABgene, Epsom, UK). First
strand cDNA was synthesized from 0.5 μg RNA using a reverse
transcription kit (Sigma, Poole, Dorset, UK). The quality of cDNA
was verified through amplification and detection of the GAPDH
housekeeping gene. Forward and reverse primers of VEGI (Table I)
were designed based on human VEGI sequence (GeneBank
accession no. BD131562). PCR was performed in a GeneAmp PCR
system 2400 thermocycler (Perkin-Elmer, Norwalk, CT, USA).
Conditions for PCR were 40 sec at 94˚C, 60 sec at 55˚C, 60 sec at
72˚C (35 cycles). PCR products were separated on a 1.4% agarose
gel. 
Establishment of Stable Transfectants. CHO and HEK293T cells
were transfected with 3 μg of full-length human VEGI174 coding
sequence (Table I) cloned into pcDNA3.1+ expression vector
(Invitrogen Inc., Paisley, UK) by Lipofectamine 2000. CHO-stable
transfectants of full-length human VEGI174 coding sequence were
selected for 2 weeks by 2 mg/ml G418 (Invitrogen Inc., Paisley,
UK) before being subjected to cloning by limiting dilution. 
Western-blotting analysis. CHO or HEK293T cells (1×106) at 48 h
after transient transfection with 3 μg of full length VEGI174 using
Lipofectamine 2000 (Invitrogen Inc., Paisley, UK), or the same
number of the CHO stable cloned VEGI174 were lysed in 200 μl
of lysis buffer (50 mm NaCl, 20 mm Tris, pH 7.6, 1% Nonidet P-
40, 1× protease inhibitor mixture) for 1 h. The lysates were cleared
by centrifugation at 16,000 × g at 4˚C for 10 min. Crude protein
concentration was measured by DC Protein Assay kit (Bio-Rad) and
ELx800 spectrophotometer (Bio-Tek™). Two hundred μg of total
protein of each sample was transferred to a new microcentrifuge
tube, and immunoprecipitation was performed with 2 μg of the
indicated antibodies and 50μl of protein-G slurry for overnight
incubation. Ten μl of the precipitated materials were subjected to
Western blot analysis with the indicated antibodies. Primary
antibody was incubated with the membrane in the dilution
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recommended by the manufacturer. The bound primary antibody
was visualized with HRP-conjugated secondary antibody using
Supersignal™ West Dura system (Pierce Biotechnology, Inc.,
Rockford, IL, USA) and photographed using an UVITech imager
(UVITech, Inc., Cambridge, UK). 
Affinity purification of flag-tagged VEGI174 and mass spectrometry.
Flag tagged VEGI174 was stably expressed in HEK293T cells. Two
liters of cell culture was harvested and treated with or without 20
Gy IR. Four hours after IR treatment, cells were lysed with 40 ml
NETN buffer on ice for 10 min. Cell lysates were centrifuged at
12,000g at 4˚C for 20 min. Soluble fraction was collected and
insoluble fraction was washed three times with PBS and then treated
with 50 units of micrococcal nuclease on ice for 1 h and centrifuged
at 12,000g at 4˚C for 20 min. The supernatant was the chromatin
fraction combined with the NETN soluble faction. Cell lysates were
incubated with 500μl streptavidin conjugated beads (Amersham,
Tokyo, Japan) at 4˚C for 2 h. The beads were washed three times
with NETN buffer, and then bead-bound proteins were eluted with
1 ml PBS containing 2mM biotin (Sigma, Poole, Dorset, UK). The
eluted supernatant was incubated with 50 μl S beads (Novagen,
California, US) at 4˚C for 2 h. The beads were washed three times
with NETN buffer and subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. The gels were digested, and the
peptides were analyzed by liquid chromatography-tandem mass
spectrometry. 
Mass Spectrometric Analysis. MALDI quadrupole time-of-flight
mass spectrometry (Applied Biosystems/MDS Sciex QSTAR
Pulsar) was used to identify VEGI174 associated proteins by
peptide mass fingerprinting and the peptide sequence information
was obtained by MS/MS analysis. The peptide masses and the
amino acid sequences identified from the peptide fragmentation data
were subjected to MASCOT and PROSPECTOR searching engines. 
Genomic analysis of RCC tissues. For transcriptome sequencing
(RNA-seq) of renal cell carcinoma tumor tissues, snap frozen
samples were used to extract RNA. Its purity and integrity were
checked by Agilent Bioanalyzer prior to RNA sequencing. Only
RNA samples with RIN >7 and 28S/18S >1 were proceeded for
library construction and sequencing. The sequencing was performed
at PE125 on an Illumina HiSeq2500 platform by certified Illumina
service providers. Transcript expression was estimated by MMSEQ
(19) and represented by log2 (FPKM). 
Immunohistochemical staining of renal specimens. Frozen
specimens of renal cell carcinoma (n=16) and normal renal tissue
(n=16) were cut at a thickness of 6μm using a cryostat (Leica CM
1900, Leica Microsystems UK Ltd., Buckinghamshire, UK). The
nature of the samples was independently verified by two
pathologists. After fixation, the sections were blocked with horse
serum and probed with or without VEGI174, ACLY, ENO1 or
AKR1C3 antibodies for 1 h. The secondary biotinylated antibody
and the avidin-biotin complex were subsequently applied to detect
VEGI expression in accordance with the Vectastain Universal Elite
ABC kit protocol (Vector Laboratories, Peterborough, UK). After
developing color with DAB, the sections were counterstained with
Gill’s hematoxylin. Staining was independently assessed by the
authors. 
Statistical analysis. Statistical analysis was performed using the
SPSS 19.0 software. The two sample t-test was used for normally
distributed data. Fisher’s exact test was used for analyzing
immunohistochemical staining in renal cancer tissues. Differences
were considered to be statistically significant at p<0.05.
Results
Genetic manipulation of VEGI levels in HEK293T and CHO
cell lines. HEK293T and CHO cells were transfected with a
VEGI expression construct to create sublines showing
enhanced levels of VEGI expression. VEGI174 was
transfected into CHO as a positive control of HEK293T. As
shown by RT-PCR analysis, VEGI mRNA expression was
significantly increased in HEK293TVEGI and CHOVEGI cells
compared with wild-type (Figure 1A). Western Blot
demonstrated that VEGI protein expression was significantly
increased in HEK293TVEGI and CHOVEGI cells compared to
wild-type cells (Figure 1B).
Results of Mass Spectrometric Analysis. VEGI174 was
purified using ANTI-FLAG affinity resin. Protein samples
were eluted by gradient FLAG peptide from 300 to 1000ug/ml
(Figure 2). The gels were digested, and the peptides were
analyzed by liquid chromatography-tandem mass
spectrometry. The common non-specific associated proteins,
including acetyl coenzyme A carboxylase 1, pyruvate
carboxylase, methylcrotonoyl coenzyme A carboxylase
subunit alpha, heat shock protein superfamily and myosins,
are not listed in the mass spectrometry results shown in Table
II. There were five proteins that may interact with VEGI174. 
RNAseq analysis of renal cell carcinoma tissues. The
expression of genes was examined in 16 RCC tissues by
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Table I. PCR primer sequences.
Primer                                                       Forward                                                                            Reverse
hGAPDH                                                   5’-AGCTTGTCATCAATGGAAAT                               5’-CTTCACCACCTTCTTGATGT
VEGI                                                         5’-ATGAGACGCTTTTTAAGCAA                              5’-CTATAGTAAGAAGGCTCCAAAG
VEGI (expression)                                    5’-ATGAGACGCTTTTTAAGCAA                              5’-CTATAGTAAGAAGGCTCCAAAGA
RNAseq. In the present study, we analysed more than five
genes which may interact with VEGI174. Comparing against
the TCGA database, the expression level of VEGI174
(–0.4626) in RCC was lower than that in normal kidney
(p=0.006). The expression levels of ACLY (6.6992),
AKR1C3 (6.3558), ENO1(4.330), ZIK1(0.5451) and MYC
(5.2869) in RCC were higher than that in normal kidney (p-
values were 0.001, 0.0045, 0.001, 0.002, and 0.001,
respectively). 
In stage T1 group, the expression level of AKR1C3 was
lower than that of stage T3 group, p=0.003. The expression
level of ENO1 in stage T1 was higher than that of stage 3
group, p=0.029. However, there were no differences in the
expression levels of VEGI, ACLY, MYC and ZIK1, p=0.114,
0.502, 0.826, and 0.822, respectively. 
In addition, Fuhrman Grade1 group and Fuhrman Grade2
group were merged into a low-grade group. Fuhrman Grade3
group and Fuhrman Grade4 group were merged into a high-
grade group. The low-grade group expression level of
AKR1C3 was lower than that of the high-grade group,
p=0.001. The low-grade group expression level of ENO1
was higher than that of the high-grade group, p=0.020.
However, there were no differences in the expression levels
of VEGI, ACLY, MYC and ZIK1, p=0.261, 0.578, 0.936,
and 0.989, respectively.
Detection of VEGI174, ACLY, ENO1 and AKR1C3 protein
by immunohistochemistry. There are many researches on
MYC and ZIK1, therefore we did not detect them in this
study. In immunohistochemical staining, VEGI174 was seen
in the cytoplasmic area of normal renal tubular epithelia
cells, but the staining was decreased or absent in RCC cells,
particularly in specimens with high-grade tissues (Figure
3A). The positive staining of normal tissues (87.5%, 14/16)
was significantly higher than that of RCC tissues (31.25%,
5/16), p=0.006.
ACLY was seen in the cytoplasm of normal renal tubular
epithelia cells. The staining was seen in the cell membrane
ANTICANCER RESEARCH 37: xxx-xxx (2017)
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Table II. Five proteins that may interact with VEGI174.
Mass                                                 Protein Name                                           NBCI ID (Homo sapiens)                             UnitProt database
121342                                   ATP citrate lyase (ACLY)                                            Gene ID: 47                      http://www.uniprot.org/uniprot/P53396
97665                Aldo-ketoreductase family 1 member C3(AKR1C3)                     Gene ID: 8644                    http://www.uniprot.org/taxonomy/9606
54721             zinc finger protein interacting with K protein 1 (ZIK1)                Gene ID: 284307                 http://www.uniprot.org/uniprot/Q3SY52
47111                                     enolase 1 variant  (ENO1)                                        Gene ID: 284307                  http://www.uniprot.org/uniprot/P06733
36532                                  C-myc proto-oncogene, MYC                                       Gene ID: 4609                    http://www.uniprot.org/uniprot/P01106
Figure 1. Confirmation of manipulation of VEGI174 expression in HEK293T and CHO cells. A: Verification of forced expression of the VEGI174
transcript in HEK293T and CHO cells. VEGI174 mRNA expression in the HEK293T and CHO cells was higher than that in wild type cells. B:
Forced expression of VEGI174 at the protein level using western Blot analysis of HEK293T and CHO cells. VEGI174 protein level was increased
in HEK293T and CHO cells compared with that of wild-type cells.
and cytoplasm of RCC tissues (Figure 3B). However, there
was no significant difference of ACLY expression between
normal renal and RCC tissues, p=0.342.
ENO1 was seen in the cytoplasmic and nucleus area of
normal renal tubular epithelia cells. The staining was also seen
in the cytoplasmic and nucleus area of RCC tissues (Figure
3C). However, there was no significant difference of ENO1
expression between normal renal and RCC tissues, p=0.117.
AKR1C3 was seen in the cytoplasm of normal renal
tubular epithelia cells, but the staining was increased in the
cytoplasmic and nucleus area of RCC tissues (Figure 3D).
The positive staining of normal tissues (25%, 4/16) was
significantly lower than that of RCC tissues (81.25%, 13/16),
p=0.002. Moreover, the higher expression level of AKR1C3
was seen in higher stage and grade of RCC. 
Discussion
RCC is a wide spread oncourological disease with a
tendency towards morbidity progression. At the time of RCC
diagnosis, metastatic lesions are present in 20-30% of
patients (20, 21). Also, in 20-30% of patients with
preoperative absence of metastases, after nephrectomies
metastatic lesions appear or local recurrence of disease take
places (22, 23). Surgical treatment of kidney tumors is the
only effective treatment modality. Until the 21st century, the
efficacy of drug therapy for disseminated RCC (interferon–
α, interleukins, hormonal therapy and chemotherapy) was
insignificant or absent, and the median overall survival (OS)
in metastatic disease rarely exceeded 8 months (24). It was
only in the recent decade, after deeper understanding of the
peculiarities of initiation and development of tumor
progression in RCC, that it became possible to approve more
efficacious drugs targeting key molecules involved in the
RCC carcinogenesis.
VEGI is a multipotential cytokine that plays a role in
regulating immunity, anti-angiogenesis, and inhibiting tumor
growth (16, 25). Studies have shown that overexpression of
VEGI could inhibit tumor neovascularization and
progression in cellular and animal models. Our pre-study
also showed the VEGI174 inhibitory effect on cellular
motility, adhesion, vascular endothelial tube formation and
tumor growth in vivo (15). It was suggested that VEGI174
functions mainly through inhibition of angiogenesis and is a
negative regulator of aggressiveness during the development
and progression of RCC (17). 
A few mechanisms underlying the inhibitory effect of
VEGI on angiogenesis were revealed. First, VEGI prevents
G0/G1 endothelial cells from re-entering the cell cycle in
response to growth stimuli. Second, there are two members
of the TNF receptor superfamily which VEGI interacts with,
namely death receptor 3 (DR3) and decoy receptor 3 (DcR3).
DR3 is the functional receptor of VEGI251. It contains a
death domain in its cytoplasmic tail and induces apoptosis in
death receptor-3-expressing cell lines, such as in human
umbilical vein endothelial cells (HUVECs). On the contrary,
previous studies indicated that DcR3 is overexpressed in
malignant tumors arising from the oesophagus, stomach,
glioma, lung, colon and rectum (10, 18, 26-28). DcR3
enhances angiogenesis by blocking the autocrine-angiostatic
function of VEGI in human umbilical vein endothelium (18).
Meanwhile, anti-VEGI and -DR3 antibodies lead to increases
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Figure 2. Co-immunoprecipitation of VEGI174 with its associated proteins. Co-immunoprecipitation of VEGI174 was performed by using anti-flag
monoclonal antibody conjugated beads from CHO or HEK293T cells stably transfected with flag-labeled VEGI174 expression construct. The eluent
was immunoblotted by anti-flag monoclonal antibody. 
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Figure 3. Immunohistochemical staining of human renal specimens. A1, B1, C1 and D1 were normal renal tissue. The VEGI, ACLY, Eno1 and
AKR1C3 protein was found to be stained in the cytoplasmic area of normal renal tubular epithelia cells. ENO1 was also seen in some nucleus area
of normal renal tubular epithelia cells. A2, B2, C2 and D2 were renal cell carcinoma tissue. A2, the staining of VEGI174 was decreased or absent
in RCC cells, particularly in specimens with high-grade tissue. The positive staining of normal tissue was significantly higher than that of RCC
tissues, p=0.006. B2, the staining of ACLY was seen in cell membrane and cytoplasmic in RCC tissues. C2, the staining of ENO1 was seen in
cytoplasmic and nucleus area of RCC tissues. There was no significant difference of ACLY and ENO1 expression between normal renal and RCC
tissues (p=0.342, p=0.117, respectively). D2, the staining of AKR1C3 was increasing in cytoplasmic and nucleus area of RCC tissues. The positive
staining of normal tissue was significantly lower than that of RCC tissues, p=0.002.
of both cell proliferation and motility, and an induction of
the formation of tube network (29). The angiogenic effect of
VEGI antibody and DR3 antibody is similar to that induced
by DcR3. Furthermore, VEGI induces apoptosis in actively
proliferating cells, via activation of the stress protein kinases,
SAPK/JNK and p38 MAPK (SAPK, stress-activated protein
kinase, JNK, c-Jun N-terminal protein kinase, p38 MAPK,
p38 mitogenactivated protein kinase), and the caspases,
mainly caspase-3-like protease. Additionally, VEGI-induced
apoptosis is attenuated by a caspase inhibitor.
However, it is still unclear whether VEGI174 acts solely or
in collaboration with binding proteins in the form of a protein
complex. In this study, we showed that there were five
proteins that may interact with VEGI174. For MYC, it is well
known that its pathway is activated in most cases of human
RCC. The MYC oncogene contributes to tumorigenesis of
many types of cancer through various mechanisms (30-33),
including the regulation of proliferation and growth, protein
and ribosomal biogenesis, changes in metabolism, lipid
synthesis, and induction of angiogenesis (34-37). For Zinc
finger protein interacting with K protein 1 (ZIK1), was first
described in 1996 by Denisenko et al. (38). In addition to the
nine contiguous zinc fingers in the C-terminus, ZIK1 contains
a KRAB-A domain thought to be involved in transcriptional
repression. ZIK1 demonstrated aberrant DNA methylation, it
might function on tumor development (39). It was unknown
whether there was a relationship between decreasing VEGI174
expression level and increasing MYC or ZIK1 expression
levels in RCC tissues. There are many studies that have
reported MYC and ZIK1 expression and function, thus we did
not examine them with IHC.
Contrary to the decreasing expression level of VEGI174,
three other factors increased in RCC tissues. The first, ACLY
was an important enzyme involved in lipid biogenesis that is
linked with glucose metabolism. Studies have shown a role
for ACLY in tumorigenesis whereby increased levels of the
enzyme leads to increased metabolic activity via activation
of Akt signaling. Increasing lines of evidence suggest that
enzymes involved in lipid biogenesis play a significant role
in cancer cell proliferation and progression. In many cancer
types such as glioblastoma, colorectal cancer, breast cancer,
non-small cell lung cancer, hepatocellular carcinoma etc., the
level of ACLY has been found to be quite high as compared
to normal cells (40-43). In this study, mRNA levels of ACLY
in RCC were higher than that in normal tissues. The IHC did
not show the same result. Normal renal and RCC tissues all
had positive staining. However, in RCC tissues, the staining
was seen in all areas of the cell, including cell membrane,
cytoplasm and nucleus. In normal renal tissues, ACLY was
only seen in the cytoplasmic area of renal tubular epithelia
cells. We could not explain this kind of difference. 
Secondly, ENO1 generates ATP during glycolysis. Several
studies have shown that ENO1 is a multifunctional protein
participating in several physiological processes, including
growth control, hypoxia tolerance and autoimmune activities
(44, 45). Remarkably, accumulating evidence have suggested
that ENO1 can function as an oncogenic protein by
promoting cell proliferation, invasion and metastasis. ENO1
expression is frequently increased in diverse tumors,
including head and neck, thyroid, breast, lung, prostate,
colon and gastric cancer, glioma and cholangio carcinoma
(46-49). Moreover, overexpression of ENO1 is positively
associated with progression and poor prognosis in several
tumors (49). Up to now, the role of ENO1 in RCC remains
unknown. In this study, ENO1 expression was higher in RCC
than that in normal renal according to the results of RNAseq
and IHC. However, contrary to other tumors, the ENO1
expression level in the low stage and grade group was higher
than that in the high stage and grade group.
Thirdly, AKR1C3 was originally cloned from human liver
and prostate cDNA libraries (50, 51). It is a monomeric
cytoplasmic protein of 323 amino acids and a molecular
weight of 37 kDa (52, 53). AKR1C3 is overexpressed in
numerous cancers, including cancers of the prostate, breast,
uterine, blood, lung, brain and kidney, whereas its
upregulation frequently correlates with tumor invasiveness
and aggressiveness (54-61). In this study, mRNA level of
AKR1C3 in RCC was higher than that in normal tissues.
Moreover, the higher expression level of AKR1C3 was
positively correlated with higher RCC stage and grade. This
is contrary to the reduction of VEGI174 in higher RCC stage
and grade. IHC results also suggested this kind of
correlation. So, AKR1C3 may correlate with the progression
of RCC.
In conclusion, in this study, five proteins were found to
interact with VEGI174. It is still unclear whether VEGI174
acts in collaboration with other binding proteins in form of
a protein complex. In contrast to the decrease in VEGI174
expression in RCC tissues, the expression of the above five
proteins was increased in RCC tissues. Based on other
studies, overexpression of the above five proteins is
associated with progression in several tumors. The exact
function of those five proteins is unknown in RCC. We
didn’t know the relationships between VEGI174 and above
five proteins too. However, the results indicated that
VEGI174 has more functions than we now know in the
supression of the development and progression of RCC.
Therefore, further studies should be performed to clarify this
matter. Moreover, the expression of AKR1C3 was correlated
with high-grade and high-stage RCC. It is suggested that
AKR1C3 not only interacts with VEGI174, but also closely
relates with the progression of RCC. 
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